Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 10, 2020Journal of Pharmacology and Experimental TherapeuticsOpen Access

The Pharmacological Case for Cannabigerol

View Full Paper
Ask AI
Bookmark
Share

Authors

RNRahul NachnaniPennsylvania State UniversityWRWesley M. Raup‐KonsavageIo Therapeutics (United States)KVKent E. VranaPennsylvania State University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nachnani et al. (2020) studied this question.

synapsesocial.com/papers/6a709702ac440176ef29402bhttps://doi.org/10.1124/jpet.120.000340
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor2018 · 66 citations
  2. 2Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT1A somatodendritic autoreceptors in the dorsal raphe nucleus2011 · 257 citations
  3. 3Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol1998 · 230 citations
  4. 4Cannabis, Cannabinoids, and the Endocannabinoid System—Is there Therapeutic Potential for Inflammatory Bowel Disease?2018 · 72 citations
  5. 5Dexmedetomidine: A Novel Sedative-Analgesic Agent2001 · 863 citations